Background Image
Table of Contents Table of Contents
Previous Page  2 / 48 Next Page
Information
Show Menu
Previous Page 2 / 48 Next Page
Page Background

Dyna Gliclazide SR 30 mg

. Each modified release tablet contains 30 mg gliclazide. Reg. No.: RSA S3 42/21.2/0249 NAM NS2 12/21.2/0110. For full prescribing information, refer to the package insert approved by the Medicines

Control Council, 10 December 2011.

1)

Crepaldi G and Fioretto P. Gliclazide modified release: Its place in the therapeutic armamentarium. Metabolism 2000;49(10)supplement 2:21-25.

2)

McGavin JK,

et al

. Gliclazide modified release.

Drugs 2002;62(9):1357-1364.

3)

The 2012 SEMDSA guideline for the management of type 2 diabetes - Glucose control: Non-insulin therapies. JEMDSA 2012;17(2):S23-S31.

4)

Department of health website

http://www.doh.gov.

za

– Accessed 26 March 2015. * Sulphonylureas

DGLD199/06/2015

.

for

SUSTAINED

CONTROL

R46,94

SEP excl. VAT

Once daily formulation

Improved compliance

1

Sustained 24 hour glycaemic control

2

SUs* are the preferred add-on therapy to metformin

3

60

s

Packed in

23

%

less

vs.

market

leader

4

For further product information contact

PHARMA DYNAMICS

P O Box 30958 Tokai Cape Town 7966

Tel

021 707 7000

Fax

021 701 5898

Email

info@pharmadynamics.co.za

CUSTOMER CARE LINE

0860 PHARMA (742 762)

www.pharmadynamics.co.za